Finerenone (Kerendia)
A prescription pill that contains finerenone, a non-steroidal medicine that blocks the mineralocorticoid receptor. In the FIDELIO-DKD trial finerenone lowered the risk of kidney disease getting worse in people with chronic kidney disease and type 2 diabetes. This record does not list approved uses because no Kerendia label record was found.
Also called Kerendia
- Product
- In this atlas
Overview
Technical summary
FDA application NDA215341, applicant listed as BAYER HLTHCARE. Original approval on 2021-07-09 (ORIG-1, Type 1 - New Molecular Entity). Dosage form TABLET. openFDA returned no label record for the brand, so no indication text was read.
Product details
- Type
- Medicine
- Model or formulation
- Tablet (dosage form TABLET on the openFDA record); several strengths.
- Version
- Not stated in the sources read. The application covers several strengths and presentations.
Intended-use sources
No intended-use source is recorded.
Claims and evidence
Context United States FDA original approval of a new drug application (NDA)
- Recipient
- Recipient not specified
- Population
- Not stated in the FDA application records read. The records give the applicant, the products and the submission history; the label record gives age limits for each indication.
- Care setting
- Not stated in the FDA records
- Geography
- United States (decision by the US Food and Drug Administration)
- Life stage
- Not stated in the FDA records
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The US Food and Drug Administration approved Kerendia (finerenone tablets) on 9 July 2021 under new drug application NDA215341. The Drugs@FDA page lists the original submission as ORIG-1, an approval, classified Type 1 - New Molecular Entity. The openFDA record lists the applicant as BAYER HLTHCARE.
Applies to Recipient not specified- Not stated in the FDA application records read. The records give the applicant, the products and the submission history; the label record gives age limits for each indication.
- Not stated in the FDA records
- United States (decision by the US Food and Drug Administration)
- Not stated in the FDA records
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The date comes from the Drugs@FDA page, which writes it as a month-first slash date. The openFDA record gives the date only as a compact number, so the page is quoted. No label record for Kerendia was returned by openFDA, so this atlas states no indication. openFDA says not to rely on it for decisions about medical care.
- Last checked
- 2026-10-14
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
Supports FDA New Drug Application NDA215341: Kerendia (openFDA drugsfda record)
- Locator
- results[0].application_number; results[0].sponsor_name
- How it applies
- Application number and applicant.
- Retrieved
- Source effective date
- 2026-10-13
- Source state
- Current
- Snapshot hash
3ad75e163b866653015aee0b31d67725c3aaf788abe55d149f53d65ab1f3385e- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-14 as ch-openfda-terms.html, sha256 b11f712bfb11, hash only). The raw record is committed at research/snapshots/ch-openfda-nda215341.json.
-
Supports Drugs@FDA: approval date(s) and history for NDA 215341 (Kerendia)
- Locator
- Original Approvals or Tentative Approvals, Action Date (MM/DD/YYYY)
- How it applies
- Original approval date.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Snapshot hash
1dbf2f78139897b5d65087d562dd452e07f39893a5c534b4c76ec8b0b669d490- Reuse basis
- The FDA website policies page (fetched 2026-10-14 as ch-fda-website-policies.html, sha256 59b7c8541753, hash only) says that, unless otherwise noted, the contents of the FDA website (www.fda.gov) are not copyrighted and are in the public domain. This page is on the accessdata.fda.gov host of FDA; the policy page names www.fda.gov only, so the terms for this host are unverified and the source is cite_only: facts are stated in the atlas's own words, with no quoted span. The raw page is committed at research/snapshots/ch-fda-daf-nda215341.html.
-
Supports FDA New Drug Application NDA215341: Kerendia (openFDA drugsfda record)
- Locator
- results[0].submissions[3].submission_type; results[0].submissions[3].submission_status; results[0].submissions[3].submission_class_code_description
- How it applies
- Original submission, its status and classification.
- Retrieved
- Source effective date
- 2026-10-13
- Source state
- Current
- Snapshot hash
3ad75e163b866653015aee0b31d67725c3aaf788abe55d149f53d65ab1f3385e- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-14 as ch-openfda-terms.html, sha256 b11f712bfb11, hash only). The raw record is committed at research/snapshots/ch-openfda-nda215341.json.
-
Background FDA New Drug Application NDA215341: Kerendia (openFDA drugsfda record)
- Locator
- results[0].products[0].active_ingredients[0].name
- How it applies
- Active ingredient on the application record.
- Retrieved
- Source effective date
- 2026-10-13
- Source state
- Current
- Snapshot hash
3ad75e163b866653015aee0b31d67725c3aaf788abe55d149f53d65ab1f3385e- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-14 as ch-openfda-terms.html, sha256 b11f712bfb11, hash only). The raw record is committed at research/snapshots/ch-openfda-nda215341.json.
Authorization
Regulatory decision: Finerenone (Kerendia)
- Not stated in the FDA application records read. The records give the applicant, the products and the submission history; the label record gives age limits for each indication.
- Not stated in the FDA records
- United States (decision by the US Food and Drug Administration)
- Not stated in the FDA records
- Gestational age Not reported
- Postnatal age Not reported
- Authority
- U.S. Food and Drug Administration
- Decision
- Approval,
- Pathway
- NDA
- Submission
NDA215341- Jurisdictions
- United States; note: United States
- Product version
- Kerendia (finerenone) tablets, application NDA215341, original submission ORIG-1
- Indication
- Not stated in the sources read. openFDA returned no label record for Kerendia.
- Basis
- The US Food and Drug Administration approved Kerendia (finerenone tablets) on 9 July 2021 under new drug application NDA215341. The Drugs@FDA page lists the original submission as ORIG-1, an approval, classified Type 1 - New Molecular Entity. The openFDA record lists the applicant as BAYER HLTHCARE.
Limitations. An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The date comes from the Drugs@FDA page, which writes it as a month-first slash date. The openFDA record gives the date only as a compact number, so the page is quoted. No label record for Kerendia was returned by openFDA, so this atlas states no indication. openFDA says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:kerendia- Content hash
2476aba340bcccd6df3c7e4d8f8b8870dad5ec3b995cecf4ac71f11becc5afb4